Categories Earnings, Health Care

Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot

— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.

— Total revenue stood at $1.96 million vs. $3.68 million expected.

Earnings Update by AlphaStreet

— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.

— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.

— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.

— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year

Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings

Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop

Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported

Is Zoom Video Communications (ZM) a good investment after Q3 earnings?

Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top